Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

NCT07313202 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07313202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07313202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 10, 2025
Completion date
December 26, 2028
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

patients with advanced solid tumors who discontinued treatment due to irae